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Abstract
Background: Down regulation of genes coding for nucleoside transporters and drug metabolism responsible for uptake
and metabolic activation of the nucleoside gemcitabine is related with acquired tumor resistance against this agent.
Hydralazine has been shown to reverse doxorubicin resistance in a model of breast cancer. Here we wanted to investigate
whether epigenetic mechanisms are responsible for acquiring resistance to gemcitabine and if hydralazine could restore
gemcitabine sensitivity in cervical cancer cells.
Methodology/Principal Findings: The cervical cancer cell line CaLo cell line was cultured in the presence of increasing
concentrations of gemcitabine. Down-regulation of hENT1 & dCK genes was observed in the resistant cells (CaLoGR) which
was not associated with promoter methylation. Treatment with hydralazine reversed gemcitabine resistance and led to
hENT1 and dCK gene reactivation in a DNA promoter methylation-independent manner. No changes in HDAC total activity
nor in H3 and H4 acetylation at these promoters were observed. ChIP analysis showed H3K9m2 at hENT1 and dCK gene
promoters which correlated with hyper-expression of G9A histone methyltransferase at RNA and protein level in the
resistant cells. Hydralazine inhibited G9A methyltransferase activity in vitro and depletion of the G9A gene by iRNA restored
gemcitabine sensitivity.
Conclusions/Significance: Our results demonstrate that acquired gemcitabine resistance is associated with DNA promoter
methylation-independent hENT1 and dCK gene down-regulation and hyper-expression of G9A methyltransferase.
Hydralazine reverts gemcitabine resistance in cervical cancer cells via inhibition of G9A histone methyltransferase.
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Introduction
Gemcitabine (29,29-difluoro 29deoxycytidine, dFdC) is an
analog of cytosine arabinoside that possesses distinctive pharma-
cological properties and wide antitumor-spectrum activity. Gem-
citabine has significant clinical activity against a number of
malignancies including pancreatic, lung, bladder, breast, ovarian
and head and neck [1,2]. In cervical cancer gemcitabine plus
cisplatin and radiation improves survival outcomes compared with
cisplatin radiation in advanced disease and when used with
cisplatin is as effective as other cisplatin doublets against metastatic
cervical cancer [3].
Gemcitabine’s pharmacological characteristics are unique in
that two main classes of genes are essential for its antitumor effects
and resistance: membrane transporter protein-coding genes,
whose products are responsible for drug intracellular uptake,
and drug metabolism-coding genes, which catalyze its activation
and inactivation [4]. Thus, the expression of these genes is key for
tumor response and resistance to gemcitabine. Most intracellular
uptake of gemcitabine is mediated by hENT1 (human Equili-
brative Nucleoside Transporter 1). Sensitivity to nucleoside
analogs including gemcitabine in vitro and in the clinical setting
has been shown to correlate with expression of this transporter
whereas hENT1-deficient cells are highly resistant to this
nucleoside [5–8]. Patients with pancreatic and lung cancer
expressing hENT1 have higher response rates and longer median
survival after gemcitabine than subjects with low or absent hENT1
[9,10]. Regarding gemcitabine metabolism genes, dCK expression
has been associated with gemcitabine sensitivity. Cell lines selected
for resistance to nucleoside analogs have shown mutational
inactivation of dCK and dCK transfection results in resensitization
of cells to Ara-C and gemcitabine [11–12]. In cancer patients a
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[13,14]. On the other hand, diphosphorylated gemcitabine is an
inhibitor of ribonucleotide reductase, a heterotetrameric enzyme
composed of two homodimers (RRM1 and RMM2) which is key
in the synthesis of intracellular deoxynucleotide triphosphate [15].
Over expression of RRM1 and RRM2 has been associated with
gemcitabine resistance in cancer cell lines and NSCLC [16,17].
Cytidine deaminase (CDA) catalyses the deamination of cytidine,
dexoycytidine, and their analogs such as gemcitabine however, its
role mediating gemcitabine resistance is controversial [18]. These
data clearly suggest that a diminished or lack of expression of dCK
and hENT1 are crucial for gemcitabine resistance, however, the
mechanisms leading to their transcriptional silencing are yet to be
defined. Earlier studies have shown that methylation at dCK gene is
responsible for its silencing [19] however; this remains to be
demonstrated for the hENT1.
Hydralazine is a small-molecule DNA demethylating agent [20]
known to demethylate gene promoters and to induce gene
reactivation in vitro [21–24] and in vivo [25]. Used in
combination with the histone deacetylase inhibitor valproic acid
reactivates the expression of genes in cancer patients [26–28]. In
addition, hydralazine has been shown to reverse doxorubicin
resistance in a model of breast cancer [29]. As most of the work on
gemcitabine resistance has been done in pancreatic cancer cell
lines and, this drug has been extensively evaluated in cervical
cancer [30] we wanted to investigate whether epigenetic
mechanisms are responsible for acquiring resistance to this agent
and if hydralazine could restore gemcitabine sensitivity in cervical
cancer cells. Our results demonstrate that in this model,
hydralazine reverses gemcitabine resistance in a DNA methyla-
tion-independent manner.
Results
Cervical cancer cell lines were examined for the basal
expression of hENT1, dCK, RRM1, RRM2, CDA genes and then
their sensitivity to gemcitabine was evaluated. The IC50 in SiHa
cell line was .1000 mM, and it was arbitrarily considered as a
primary resistant. The IC50 for the other cell lines were: 3.3 mM,
0.3 mM and 0.1 mM for CaLo, HeLa and C33A cells, respectively
(Figure 1A). As shown in figure 1B, the basal expression of genes
coding for gemcitabine transport and metabolism which were
adjusted to actin and in reference to normal cervix, varied among
the cell lines and a relationship between levels of these genes with
the intrinsic sensitivity/resistance status to gemcitabine in these
cell lines was not found.
To investigate whether the induction of gemcitabine resistance
is related to changes in the expression of hENT1, dCK, RRM1,
RRM2, CDA genes, CaLo cells were exposed to increasing
concentrations of gemcitabine and once cells became resistant
they were treated with hydralazine at different times and
concentrations. Figure 2A shows that after five weeks, CaLo cells
acquired resistance to this antimetabolite and were able to grow at
927 mM of gemcitabine (280-fold concentration). The resistance
state was accompanied by downregulation by half of hENT1 and
dCK. RRM1 and RRM2 genes had minor changes whereas CDA
was also reduced (Figure 2B). In addition, figure 2C shows that the
down regulation of hENT1 and dCK genes occurred progressively
as resistance developed. Treatment of CaLoGR cells with
hydralazine at 2 mM for 10 days, 10 mM and 30 mM for 5 days
was able to revert gemcitabine resistance as shown in figure 2D.
The corresponding IC50s for these treatments were 1.7 mM,
2.7 mM and 6.6 mM respectively.
To determine whether the reversion of the resistance by
hydralazine which is a weak DNA demethylating agent is
accompanied by changes in the expression of hENT1 and dCK
genes, a RT-PCR of these two genes was performed. The results in
figure 3A shows that as expected hydralazine led to the re-
expression of these genes in the three treatment conditions
evaluated. DNA promoter hypermethylation has been shown to
silence genes in chemotherapy resistance models therefore the
methylation status at these promoters was evaluated by MSP.
Interestingly, hENT1 and dCK promoters were partially methylated
even in the basal state and showed no hypermethylation in the
resistant CaLoGR cell line. Hydralazine at 2 mM, 10 mMo r
30 mM failed to demethylate these promoters as shown by MSP in
figure 3B. To confirm this finding, six independent clones (basal,
resistant and resistant treated with hydralazine) were bisulfite
sequenced but no demethylation was observed in the CpG
evaluated (Fig. 3C). The gene reactivation therefore was
independent of its demethylating effect, suggesting that other
epigenetic mechanisms could account to down regulate and
reactivate these genes in this model. To confirm that the lack of
demethylating effect of hydralazine upon dCK and hENT1 was not
due to its weak demethylating ability, figure 3D shows that in the
same cell line and conditions, the gene DAPK was demethylated
with hydralazine at 2 mM1 0mM and 30 mM.
An increase of histone deacetylase activity has been shown to
induce gene silencing in some models. To determine whether this
phenomenon participates in gemcitabine resistance in cervical
cancer, the deacetylase activity was measured in CaLo cells using
a kit which contains the prototype HDAC inhibitor trichostatin A
as a positive control. Figure 4A shows that no changes in HDAC
activity were observed; actually a small decrease in deacetylase
activity was observed in the resistant cells. The evaluation of the
total acetylation at H3 and H4 in hENT1 and dCK gene
promoters by ChIP assays while showed a decrease in H3 and H4
acetylation at the hENT1 promoter, a mild increase in acetylation
of H3 was observed in the dCK promoter and no change for H4
acetylation (Figure 4B). These apparently opposite results argue
against a major role of H3 and H4 acetylation to explain the
silencing of these genes by this histone modification. Further,
valproic acid treatment at 1 mM for 5 days failed to reactivate
the expression of these genes and to reverse gemcitabine
resistance (not shown).
To gain further insight into the epigenetic mechanisms of
hENT1 and dCK silencing in this model of gemcitabine resistance,
histone methylation was assayed. Methylation of H3K9 is a known
repressive mark while methylation at H3K4 is activating, hence
the methylation at these lysines was evaluated by ChIP analysis in
the basal state, in resistant cells and after hydralazine treatment.
Figure 5 shows that for the hENT1 gene, no changes were
observed in H3K4me3 methylation but H3K9me2 mildly
increased in the resistant cells and decreased after hydralazine
treatment. Regarding the dCK gene a slight reduction in
H3K4me3 was observed in the resistant cells which was not
modified by hydralazine. Nevertheless, the methylation at
H3K9me2 mildly increased in resistant cells and reduced after
hydralazine. The changes in band intensity were normalized
against their respective input intensity. As the DNA demethylating
agent 5-aza-CdR has shown to decrease H3K9me2, we used the
MetaDrug
TM program to uncover whether hydralazine may be
involved in the regulation of H3K9 methylation. As shown in
Figure 6, hydralazine may affect not only DNA methylation in
cytosine but also can be involved in negative regulation of H3K9
methylation. To confirm these predictions the mRNA expression
of G9A was evaluated in CaLo cells by qPCR. The results show
Hydralazine Reverts Gemcitabine Resistance
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whereas hydralazine decreased its level (figure 7A). Similar results
were obtained by western blot, G9A protein increased in the
resistant cells and decreased after hydralazine treatment
(Figure 7B). To further investigate the G9A inhibitory ability of
hydralazine, a H3K9 methyltransferase in vitro inhibition assay was
performed using the EpiQuik
TM Histone Methyltransferase Activ-
ity/Inhibition Assay Kit (H3-K9). Hydralazine at 2 mM and
10 mM strongly reduced H3K9 methylation (figure 7C). To
confirm the biological significance of this in vitro finding, knockout
of the G9A gene by means of an iRNA assay showed that
transfected CaLo cells regained sensitivity to hydralazine which
was not further modified when these cells also were treated with
hydralazine (Fig. 8).
Discussion
The results of this study of gemcitabine resistance in cervical
cancer cells and its reversion with the weak DNA demethylating
agent hydralazine show that the development of resistance is
accompanied by down-regulation of key genes for gemcitabine’s
intracellular uptake and metabolism, hENT1 and dCK. Interest-
ingly, this down-regulation was not due to gene promoter
hypermethylation as demonstrated by MSP and bisulfite sequenc-
ing; nevertheless, hydralazine was able to reactivate their
expression and to revert gemcitabine resistance. These data
suggest that other epigenetic mechanisms operate to silence
chemotherapy resistance genes and that hydralazine has DNA
methylation-independent effects, most likely through affecting
Figure 1. Gemcitabine sensitivity in cervical cancer cells and basal gene expression. A. The IC50 of gemcitabine for HeLa, CaLo, SiHa and
C33A cells were 3.3 mM, 0.3 mM, .1000 mM and 0.1 mM respectively as evaluated with the crystal violet assay. B. Basal expression of hENT1, dCK,
RRM1, RRM2, CDA genes as evaluated by RT-PCR. There was no correlation between IC50 and the intrinsic sensitivity/resistance status. Expression was
adjusted to the expression in normal cervix.
doi:10.1371/journal.pone.0029181.g001
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METADRUG
TM program.
These findings are important to gain further knowledge onto the
mechanisms of chemotherapy drug resistance. Gene inactivation
by DNA methylation was the first epigenetic mechanism shown to
be directly involved in the acquisition of chemotherapy resistance
in in vitro models [31,32] however, as the knowledge on epigenetic
processes has evolved, the participation of other epigenetic players
such as histone deacetylases both zinc-and NAD-dependent as well
as histone methyltransferases, histone demethylases and micro-
RNAs in the inactivation process of genes involved in chemother-
apy sensitivity and resistance has been uncovered [33–38]. Our
results strongly suggest that in this model of gemcitabine resistance
in cervical cancer, methylation at H3K9 could be the main
mechanism for silencing the expression of hENT1 and dCK genes
which paves the way for further testing the participation of this
histone modification in other models of chemotherapy resistance.
The relevance of this finding increases as inhibitors of G9A histone
methyltransferases are being available for study [39].
Early studies have shown that the DNA methylation inhibitors
induced dCK re-expression in the CEM/dCK- cells [19] and that
the lack of expression of this key gene for activation of several
nucleoside analogs including gemcitabine occurs by promoter
methylation [40–43]. So far no other epigenetic mechanism for
silencing this gene has been described in chemotherapy resistance
models. Likewise, lack of expression or low levels of hENT1
strongly correlate with resistance to gemcitabine and other
nucleoside analogs [6,9,10,44]. Though several membrane
transporter coding-genes such as hOAT3 (SLC22A8), the solute
carrier family 5 iodidetransporter (SLC5A8), the reduced folate
carrier (RFC), the cellular retinol-binding protein 1, and the
human Na+/I-symporter are known to be down regulated by
DNA methylation and reactivated by DNA methyltransferase
inhibitors [45–49], here we were not able to demonstrate that
promoter methylation at hENT1 accounts for its observed
downregulation, yet its reactivation was achieved by hydralazine
through a DNA methylation-independent mechanism suggesting
that indeed hENT1 is down regulated by an epigenetic effect most
likely through G9A histone methyltransferase-mediated H3K9
methylation.
Despite that both genes contain CpG islands at their promoters
[50,51] and that at least for the dCK gene it has consistently been
shown that its promoter is methylated in resistant cells [19], in our
model there is no correlation between the promoter methylation at
these promoters and expression. Nevertheless, the demethylating
effect upon other genes (DAPK) was proven, ruling out that
hydralazine has no demethylating effect. These data led us to
search for other epigenetic mechanisms that could account for
gene silencing. No consistent changes in histone deacetylase nor in
histone acetylation at these gene promoters were observed ruling
out this histone modification as a silencing mechanism for these
genes in this model. As the DNA methyltransferase inhibitor 5-
Figure 2. Gemcitabine sensitivity, gene expression and effects of hydralazine in CaLo cells. A. After acquiring gemcitabine resistance, the
IC50 in CaLoGR cells was 927 mM (280-fold concentration). B. Expression of hENT1, dCK and CDA were reduced almost by half, RRM1 and RRM2 had
minor changes. C. The reduction of hENT1 and dCK genes occurred progressively as resistance developed. D. Treatment of CaLoGR cells with
hydralazine at 2 mM for 10 days, 10 mM and 30 mM for 5 days reverted gemcitabine resistance. The corresponding IC50s for these treatments were
1.7 mM, 2.7 mM and 6.6 mM respectively.
doi:10.1371/journal.pone.0029181.g002
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to DNA methylation with regard to transcriptional reactivation
such as histone H3K9 demethylation in the regulatory regions of
silenced genes [52] we performed a search in the META-
DRUG
TM program to get clues onto other possible effects of
hydralazine. Our results showed that indeed hydralazine is
predicted to be involved in the negative regulation of H3K9
methylation. This result led us to analyze by ChIP analysis for
changes in the H3K9me2 at both dCK and hENT1 promoters in
the CaLoGR cells. Both promoters contained H3K9me2 in
untreated cells, slightly increased in the resistant state, and this
silencing mark was partially relieved by hydralazine. We must
however, stress that these changes though in H3K9m2 though
consistent in three separate assays, were mild which can be
explained on the basis that at least eight histone methyltransferases
including G9A also have H3K9 as their methylation target [52].
To further confirm the finding, a quantitative RT-PCR showed
that the expression of G9A was increased in the resistant cells as
compared to sensitive cells and levels did decrease after treatment
with hydralazine. Nevertheless, a dramatic reduction at the
protein level of this histone methyltransferase was observed by
western blot in the resistant cells after hydralazine treatment.
Remarkable, these results are very similar to those found with 5-
aza-CdR in a breast cancer model of MASPIN re-expression
where reductions in G9A histone methyltransferase protein levels
are not due to effects on G9A gene expression [53]. Additional
support for this effect of hydralazine was obtained by an in vitro
assay of H3K9 methylation showing that hydralazine inhibits the
activity of this histone methyltransferase. The biological meaning
of these observations was proven by showing that depleting G9A
in the resistant CaLo cells led to regain sensitivity to gemcitabine
by these cells and that higher sensitivity to gemcitabine was not
achieved by adding hydralazine to the G9A depleted cells arguing
against an off-target effect of hydralazine.
Of note, the METADRUG
TM program also indicated that
hydralazine could act positively in the regulation of H3K4
methylation which was not observed in our study, however, recent
data from our group indicate that in several cancer cell lines
treatment with hydralazine and valproic acid led to over-
expression of MIC A and MIC B ligands which was accompanied
Figure 3. Effect of hydralazine upon hENT1, dCK expression and promoter methylation. A. Hydralazine at the three conditions tested
(2 mM for 10 days, 10 mM and 30 mM for 5 days) restored the expression of these genes. B. hENT1, dCK genes were partly methylated basally and
promoter methylation did not change in the resistant cells neither after hydralazine treatment as evaluated by MSP. C. Maps of the promoters at
these genes showing the CpG islands density and distribution as well as the positions of primers for MSP, ChIP and sequencing. It is also shown by
sequencing that the CpG methylation did not change in dCK and hENT1 genes neither in the resistant cells neither when treated with hydralazine.
Empty and filled circles represent demethylated and methylated CpGs in five independent sequencences. D. Hydralazine was able to demethylate the
DAPK promoter in the CaLo cell line.
doi:10.1371/journal.pone.0029181.g003
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suggesting that hydralazine could have this effect upon this histone
mark [54].
Either intrinsic or acquired drug resistance is a complex and
pleiotropic phenomenon and other potential players participating
in gemcitabine resistance in this model were not investigated in
this study. For instances, despite RRM1 and RRM2 over expression
has been related to drug resistance [55] no major changes were
observed at these genes in this study. Paradoxically, CD gene was
down regulated in the resistant cells despite its over-expression has
consistently been shown related with resistance to gemcitabine and
other nucleoside analogs [56]. This finding further underscores the
complexity of drug resistance which seems to be gene and cell
model-specific.
The findings of this study are of potential clinical relevance at
least for this model of drug resistance. Gemcitabine is frequently
used for cervical cancer either concurrent to radiation or in
combination with cisplatin for advanced stages [3]. Acquired
resistance to this drug may be responsible for treatment failure;
hence, hydralazine may prevent resistance and potentially increase
the efficacy of gemcitabine. In addition, the uncovering that H3K9
methylation may lead to chemotherapy resistance deserves its
testing in other experimental models.
Materials and Methods
Cell culture
The cervical cancer cell lines HeLa, SiHa and C33A were
obtained from the ATCC. The CaLo cell line was a kindly
donated by Dr. Monroy-Garcia [57]. Cell lines were cultured at
37uC in humidified atmosphere containing 5% C02 in DMEM
supplemented with 10% fetal calf serum (Gibco, Grand Island,
NY).
Cytotoxicity assays
Cells were seeded into 6-well microtiter Falcon plates (Becton
Dickinson, Franklin Lakes, NJ) at 2610
3 cells/well into 0.2 ml of
complete medium and then treated for 24 hours with gemcitabine
at concentrations ranging from 1610
28 Mt o1 610
24 M.
Thereafter, the medium containing gemcitabine was removed
and fresh medium was added. After 72 h medium was aspirated
and replaced for 10 minutes with 50 mL of 0.75% crystal violet in
50% ethanol, 0.25% NaCl, and 1.75% formaldehyde solution.
Cells were then washed with water, air-dried, and the dye eluted
with PBS+1% sodium duodecyl sulfate (SDS) solution. Cell
viability was assessed by dye absorbance measured at 570 nm
on an automated ELISA reader. All assays were performed in
triplicate. The cytotoxic effect of each treatment was expressed as
a percentage of cell viability relative to untreated control cells
(percentage of control) and is defined as [A570 nm treated cells/
A570 nm non-treated cells]6100.
Induction of gemcitabine resistance and hydralazine
treatment
CaLo cell line was cultured at 37uC in humidified atmosphere
containing 5% C02 in DMEM supplemented with 10% fetal calf
serum (Gibco, Grand Island, NY). Increasing doses of gemcitabine
(IC30,I C 50,I C 80 and finally two steps at IC90 were added weekly
to induce gemcitabine resistance. After adding IC90 twice, the
cytotoxic assay was repeated to confirm gemcitabine resistance.
Gemcitabine-induced resistant CaLo cells (CaLoGR), were
cultured at 37uC in humidified atmosphere containing 5% C02 in
DMEM supplemented with 10% fetal calf serum (Gibco, Grand
Island, NY). Thereafter, hydralazine was added at 10 mM and
30 mM for 5 days and 2 mM for 10 days. The medium containing
the drug was replenished daily.
RT-PCR
RNA was isolated from cell lines by standard methods.
Thereafter 5 mg of RNA were treated with DNAse. Reverse
transcription was done using the RNA kit PCR Core Gene Amp
R
(Applied Biosystems Roche) following the provider recommenda-
tions. GAPDH, hENT1, dCK, RRM1, RRM2, CDA genes were
amplified using the following oligonucleotide primers: GAPDH:S:
59-GAAGGTCGGAGTCAACGGATTT-39, AS:59-ATGGGT-
GGAATCATATTGGAAC-39 hENT1:S :5 9GCAAAGGAGAG-
GAGCCAAGA-39, AS: 59CCCAACCAGTCAAAGATATTG-39
dCK:S :5 9-CGATCTGTGTATAGTGACAG-39, AS: 59GTTG-
GTTTTCAGTGTCCTATG-39, RRM1:S :5 9-GCAGCTGAGA-
GAGGTGCTTT-39, AS: 59-CAGGATCCACACATCAGACA-
Figure 4. HDAC activity and promoter acetylation in CaLo cells.
A. Total histone deacetylase activity showed no major changes between
basal and resistant cells, actually a small decrease was observed in the
resistant cells as evaluated with a HDAC activity kit. B. Total acetylation
of H3 and H4 as evaluated by ChIP showed a decrease in H3 and H4
acetylation at the hENT1 promoter, a mild increase in acetylation of H3
and not change in H4 at dCK promoter.
doi:10.1371/journal.pone.0029181.g004
Figure 5. H3K9 and H3K4 methylation. For hENT1 gene, no
changes were observed in H3K4m3 methylation but H3K9me2 mildly
increased in the resistant cells and decreased after hydralazine
treatment. In dCK gene there was a slight reduction in H3K4me3 in
the resistant cells which was not modified by hydralazine. The
methylation at H3K9me2 mildly increased in resistant cells and reduced
after hydralazine. The changes in band intensity were normalized
against their respective inputs.
doi:10.1371/journal.pone.0029181.g005
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TAGAAGTCAGCATCCAAG-39, CDA: S:59 GTTGCCTTG-
TTCCCT TGTAA-39, AS: 59-TCTTGCTGCACTTCGGTA-
TG-39. PCR was performed in a total volume of 25 ml containing
cDNA, 20 pmol of primers, 200 mM dNTPs, 0.25 U Taq
polymerase, and 16buffer supplied by the manufacturer (Applied
Biosystems, Foster City, CA). PCRs were initiated by a
denaturation step at 94uC for 5 min, followed by 30 cycles at
94uC for 35 sec, 59uC for 35 sec, and 72uC for 45 sec; a final
extension was performed at 72uC for 7 min. Products were
electrophoresed in 2% agarose gels. G9A gene expression was
evaluated by quantitative RT-PCR (iCycler iQ, Bio-Rad,
Hercules, CA), using SYBR Green I dye (Bio-Rad, Hercules,
CA), using the following primers: G9A; Sense 59-CTCCGCT-
GATTTTCGAGTGTAA-39 and the antisense 59-GTCGAAG-
AGGTAAGAATCATCC-39. GUSB (human beta glucuronidase)
specific primers were used as endogenous control; sense 59-CC-
TGTGACCTTCTGAGCAA-39 and antisense 59-AAACCCTG-
CAATGGTTTCTG-39. The PCR started by incubation at 95uC
for 1 min, followed by PCR cycles of 35 sec, at 94uC, 35 sec, at
59uC, 50 sec, at 72uC, with a final extension at 72uC for 7 min.
The number of PCR cycles was determined experimentally. Data
were analyzed using the 22DDCT method and reported as the
fold change in gene expression normalized to the endogenous
control gene (GUSB) and relative to cells without treatment.
iRNA transfection assay
Gemcitabine acquired resistant cells were seeded into 24
microtitier Falcon (Becton Dickinson, Franklin Lakes, NJ) at
1.5610
5 cells/well into 0.2 ml of optimem and after 24 hours
were transfected with lipofectamine and G9A siRNA (Ambrion
cat #439242). Negative control was done with lipofectamine
RANiMAX containing siRNA Scramble (Ambrion, cat #
4390844). Cells were cultured were cultured at 37uCi n
humidified atmosphere containing 5% C02. After 72 h medium
was aspirated and RNA was extracted, as well as a cytotoxicity
assay was done.
Western blot analysis
Whole cell extracts were prepared in lysis buffer containing
50 mM tris-HCl pH 7.4, 150 mM NaCl, 0.5% Nonidet P-40,
1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride (PMSF),
0.2 mM Na3VO4 and a proteases inhibitor cocktail (Sigma).
Extracted proteins were analyzed by sodium duodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE)/immunobloting
with antibodies recognizing G9A protein (Rabbit polyclonal IgG,
anti G9A protein (Millipore, Billerica, MA), and B-Actin protein
(Santa cruz Biotechnology). Protein samples were separated in
10% polyacrylamide gels. Gels were transferred into nitrocellulose
membranes. Species-specific immunoglobulin G-horseradish per-
oxidase (IgG-HRP) secondary antibodies were purchased from
Santa Cruz Biotechnology. Membranes were revealed with a
chemoluminiscent substrate (Millipore).
Histone deacetylase assay
Assays were performed using the colorimetric HDAC activity
assay from BioVision (BioVision Research Products, Mountain
View, CA) according to manufacturer instructions. Briefly, 50 mg
of nuclear extracts from CaLo cell line were diluted in 85 mLo f
ddH20; then, 10 mLo f1 0 6 HDAC assay buffer were added
followed by addition of 5 mL of the colorimetric substrate; samples
were incubated at 37uC for 1 h. Subsequently, the reaction was
stopped by adding 10 mL of lysine developer and left for additional
30 min at 37uC. Samples were then read in an ELISA plate reader
at 400 nm. HDAC activity was expressed as relative OD values
per mg of protein sample. The kit contains negative and positive
controls that consist of nuclear extract of HeLa treated or not with
trichostatin A, respectively.
Figure 6. GO processes affected by hydralazine. MetaDrug
TM program predicted that hydralazine may affect not only DNA methylation in
cytosine but also can be involved in negative regulation of H3K9 methylation.
doi:10.1371/journal.pone.0029181.g006
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sequencing-PCR (BSP)
Genomic DNA was extracted with the extraction kit Wizard
Genomic DNA purification kit (Promega, Madison, WI), accord-
ing to manufacturer instructions. DNAs were quantified spectro-
photometrically and stored at 220uC. Bisulfite modification was
done with the Methylation Direct
TM KIT (Zymo Research, Irvine
CA) according with the manufacturer instructions. MSP primers
were designed with the Methprimer program [58] to analyze the
methylation status within the promoter region of hENT1 and dCK
genes. dCK U,S :5 9- TGGGGTAGAGGTTTTTTGTTATATG-
39, AS: 59- AACTAAAAACACTAACAAACCTACAAA- 39, dCK
M, S: 59- TGGGGTAGAGGTTTTTCGTTATAC-39, AS: 59-
CAACTAAAAACACTAACGAACCTACG- 39. HENT1 U, S:
59- TTTTGTTTATTAGGAGAGAGTAGTTGT-39, AS: 59-
ATTAAAAAATCTAAAAACCACCAAA-39. HENT1 M, S: 59-
GGTTTTGTTTATTAGGAGAGAGTAGTC-39, AS: 59-AT-
TAAAAAATCTAAAAACCACCGAA-39, PCR was performed
in a total volume of 25 ml containing bisulfite-modified DNA,
20 pmol of primers, 200 mM dNTPs, 0.25 U Taq polymerase, and
16 buffer supplied by the manufacturer (Applied Biosystems,
Foster City, CA). PCRs were initiated by a denaturation step at
94uC for 5 min, followed by 50 cycles at 94uC for 35 sec, 57uC for
35 sec, and 72uC for 45 sec; a final extension was performed at
72uC for 7 min. DAPK promoter methylation was evaluated by
MSP in CaLo cell line, before and after hydralazine treatment
with the following primers: U, S: S: 59-GGAGGATAGTTG-
GATTGAGTTAAT-39; AS:59- CAAATCCCTCCCAAACAC-
CAA-39; M, S:59-GGATAGTCGGATCGAGTTAACGT-39;
AS: 59- CCCTCCCAAACGCCGA-39. The PCR mixture
contained 2 ml of 106 PCR buffer, 0.5 U of Taq Gold
polymerase, dNTP’s (each 1.25 mM), 100 ng of primers and
bisulfite-modified DNA in a final volume of 20 ml. Conditions
were 95uC for 10 min followed by 35 cycles of 95uC for 30 sec,
56uC for 30 sec and 72uC for 35 sec, with a final extension cycle of
72uC for 6 min. Primers for BSP were also designed using
methprimer program [58], to sequence from 21000 to 2115
region of hENT1 promoter: hENT1, S:5 9-GGTGGAGAGATTA-
GATTTGTAGAG-39, AS:5 9-AATCAAAAAAAACAAACAAA-
AAAAC-39; and hENT1, S:5-TTATATAAATGGGGAGTAG-
GAGAGG-39, AS:5 9-CCCAAAAACTTCCTAATTACTAACC-
39; and from 2420 to +5 region of dCK promoter: dCK,S:5 9-
TTTGTTTATTTTTAATAGGTTTATTAGAGA-39, AS:5 9-T-
CTACCCCAAACCAACAAAC-39; and dCK, S:5 9-GGTTT-
GGGGTAGAGGTTTTT-39, AS: 59-CTAAACCAAATCCTA-
ACCTACC-39. PCR was performed in a total volume of 25 mL
containing cDNA, 20 pmol of primers, 200 mM dNTPs, 0.25 U
Taq polymerase, and 16 buffer supplied by the manufacturer
(Applied Biosystems, Foster City,CA). PCRs were initiated by a
denaturation step at 94uC for 5 min, followed by 50 cycles at 94uC
for 35 sec, 57uC for 35 sec, and 72uC for 45 sec; a final extension
was performed at 72uC for 7 min. PCR amplicons were purified
and cloned into the pGEM-T-Easy vector (Promega) for
sequencing using the T7 primer. At least five clones were selected
randomly for DNA sequencing. Sequencing reactions were
electrophoresed on an ABI3100 genetic analyzer. Electrophero-
grams were analyzed in both sense and antisense direction for
presence of methylated or unmethylated CpG islands.
ChIP analysis
Cells were treated with 1% formaldehyde at room temperature
for 10 min under constant agitation. The reaction was stopped by
the addition of glycine to a final concentration of 125 mM. Cells
were washed twice in ice-cold PBS 16, resuspended in lysis buffer
(50 mM Hepes-KOH pH7.9, 10 mM EDTA pH 8.0, 1% SDS)
containing protease inhibitors, and sonicated on ice until cross-
linked chromatin was sheared to an average DNA fragment length
of 0.5–1 Kb. After centrifugation, soluble cross linked chromatin
was diluted 1:10 in immunoprecipitation (IP) buffer (10 mM
Hepes-KOH pH 7.9, 1% Triton X-100, 150 mM NaCl, and
protease inhibitors) divided into aliquots and stored at 270uC.
Protein A-Agarose (Millipore) was blocked with BSA (1 mg/mL)
and Salmon-sperm DNA (Sigma-Aldrich) and in IP buffer for 4–
6 h at 4uC and subsequently washed extensively with IP buffer
before use. Chromatin preparations were pre-cleared by incuba-
tion with blocked protein A-agarose for 2 h at 4uC. The protein A-
agarose was removed by centrifugation; the pre-cleared chromatin
was incubated with antibody (anti acetyl-histone H3, anti-acetyl-
histone H4, anti-H3K4me3, and anti-H3K9me2 (Millipore,
Billerica, MA) for 12–14 h at 4uC. Immunoprecipitates were
recovered by incubation with fresh blocked protein A-agarose for
2 h at 4uC, followed by low-speed centrifugation. The pellets were
Figure 7. Effect of hydralazine upon G9A histone methyltrans-
ferase. A. Quantitative RT-PCR of G9A shows that resistant CaLoGR cells
had an increase as compared to basal and that hydralazine reduces its
expression (basal vs resistant, p,0.05). B. At protein level, there was an
increase in G9A in the resistant cells that decreased after hydralazine
treatment. C. H3K9 methyltransferase in vitro inhibition assay.
Hydralazine at 2 mM and 10 mM strongly reduced H3K9 methylation
(untreated vs hydralazine, p,0.05).
doi:10.1371/journal.pone.0029181.g007
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buffer (10 mM Tris-HCl pH 8.0, 0.25 mM LiCl, 0.5% NP-40,
0.5% sodium deoxycholate, 1 mM EDTA pH 8.0), and three
times in Tris-EDTA (TE) pH 8.0. Precipitates were then extracted
by incubation with elution buffer (50 mM Tris pH 8.0, 1% SDS,
50 mM NaHCO3, 1 mM EDTA pH 8.0), and formaldehyde
crosslinks were reversed by treatment with a 1/25 volume of 5 M
NaCl for 8 h at 65uC. The DNA was purified by extraction with
phenol and ethanol precipitation and analyzed by PCR with the
specific primers (for hENT1, S:5 9-CCTGTGACAGAGAG-
GAACTAAG-39, AS:5 9-GCGACAACATCGATGATGACTG-
39; for dCK, S:5 9-CCTCCCCACCCGACTCCGGAACC-39, AS:
59-CAGCTGAGGACACTGGCGGGCCTG-39). PCR was per-
formed in a total volume of 25 ml containing DNA, 20 pmol of
primers, 200 mM dNTPs, 0.25 U Taq polymerase, and 16buffer
supplied by the manufacturer (Applied Biosystems, Foster City,
CA). PCRs were initiated by a denaturation step at 94uC for
5 min, followed by 35 cycles at 94uC for 35 sec, 59uC for 35 sec,
and 72uC for 45 sec; a final extension was performed at 72uC for
7 min. PCR products were separated on a 2% agarose gel and
visualized by ethidium bromide staining.
Prediction of processes affected by hydralazine
Hydralazine structure (primary accession number DB01275)
was downloaded from (www.drugbank.ca/drugs/DB01275) and
loaded into the MetaDrug
TM (http://www.genego.com) program.
MetaDrug
TM combines a suite of chemical structural analysis tools
(metabolite prediction, QSAR, structural similarity searching), a
comprehensive structure-activity database, and a systems biology
database of molecular interactions (protein-protein, compound-
protein, protein-enzymatic reaction, compound-enzymatic reac-
tion), canonical signaling and metabolic pathways, and gene-
biological property associations (gene-function, gene-disease, gene-
toxicity, etc.). MetaDrug
TM was set up to compile list of targets
based on known targets of the hydralazine and targets of
compounds with at least 70% similarity to input molecule. The
resulting list was subjected to enrichment analysis across GeneGo
Pathway Maps.
In vitro Histone methyltransferase assay
H3K9 methyltransferase in vitro inhibition by hydralazine was
evaluated using the EpiQuik
TM Histone Methyltransferase Activ-
ity/Inhibition Assay Kit (H3-K9) Epigentek, Brooklyn, NY) which
contains recombinant G9A as the control enzyme. The assay was
done following to the manufaturer’s protocol.
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Figure 8. iRNA assay for G9A and gemcitabine resistance. A. Inhibitory concentration of gemcitabine in CaLo cells not reached. B. Depletion
of G9A restored gemcitabine sensitivity (IC50 10.3 mM). C. No further changes in IC50 were seen when hydralazine was added to the G9A depleted
cells. D. qPCR of G9A confirming the partial depletion of G9A messenger.
doi:10.1371/journal.pone.0029181.g008
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